WebJan 17, 2024 · Under replication stress, CHK1 is associated with phosphorylated Claspin, which enhances ATR-dependent phosphorylation and supports recruitment of CHK1 to the replication fork [ 15 ]. Thus, ATR-mediated phosphorylation of CHK1 activates DNA repair and the intra-S phase checkpoint. WebFeb 16, 2024 · In addition to the involvement of E2F1 upstream of DNA replication stress, this manuscript also considers the role of E2F1 as a downstream effector of the response to this type of cellular stress. ... Chk1 is responsible for the deactivating phosphorylation on E2F6 in response to DNA replication stress, thereby promoting E2F transcriptional ...
ASPM promotes ATR-CHK1 activation and stabilizes …
WebFeb 11, 2024 · Interestingly, CHK1 inhibition overcame the resistance of replication stress to HU in KRASmut cells (Fig. 3g, Suppl. Fig. S3G), which trended toward a correlation with higher levels of γ-H2AX ... WebApr 8, 2024 · Replication stress can be defined as the stalling and collapsing of the replication machinery. This can cause serious DNA damage, such as double-stranded breaks. However, cells can mitigate... richard mason history of a pleasure seeker
Chromatin as a Platform for Modulating the Replication Stress …
WebJan 17, 2024 · Under replication stress, CHK1 is associated with phosphorylated Claspin, which enhances ATR-dependent phosphorylation and supports recruitment of CHK1 to … WebThe ATM/CHK2 and ATR/CHK1 pathways are activated by DNA double-strand breaks or by DNA single-strand breaks and replication stress, respectively. Cell cycle checkpoints are induced primarily through p53, CHK2, CHK1 and p38/MK2, which are phosphorylated by ATM and ATR. Activated p53 leads to G1-phase arrest and induces apoptosis. WebApr 15, 2024 · The high toxicity of CHK1 inhibitors is consistent with the central role of CHK1 in mediating the S phase checkpoint upon replication stress, both in the absence and presence of ATR, and in preventing premature entry into mitosis ( 55, 66 ), but presents the possibility of targeting downstream effectors of CHK1 therapeutically. richard mason knoxville